Timeline of the Ronald Reagan presidency (1981)

Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study

Retrieved on: 
Monday, July 18, 2022
Surgery, Medical Devices, Finance, Clinical Trials, Professional Services, Health, University, Optical, Education, Baylor College of Medicine, Argus retinal prosthesis, SEC, Research, National, Electrode, Disease, Timeline of the Ronald Reagan presidency (1981), Second Sight, Security (finance), Eye injury, Prospectus, U.S. Securities and Exchange Commission, Communication, NIH, Ronald Reagan, Forward-looking statement, Diabetic retinopathy, Population, Visual cortex, NPM, UCLA, Perception, Baylor University, NASDAQ, Form, COVID-19, Ronald Reagan UCLA Medical Center, Company, Light, Memorandum, Orion, Glaucoma, Severe cognitive impairment, Medical device, Risk management, Second

The funding supports continuation of this important research and testing of the Orion Visual Cortical Prosthesis.

Key Points: 
  • The funding supports continuation of this important research and testing of the Orion Visual Cortical Prosthesis.
  • Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses.
  • An early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prostheses that are intended to deliver useful artificial vision to blind individuals.

Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study

Retrieved on: 
Wednesday, August 11, 2021
White House, Federal Government, Public Policy, Government, Health, Medical Devices, General Health, Clinical Trials, Optical, Argus retinal prosthesis, National, Company, Eye injury, UCLA, Ronald Reagan UCLA Medical Center, Baylor College of Medicine, Ronald Reagan, Forward-looking statement, Timeline of the Ronald Reagan presidency (1981), Memorandum, Diabetic retinopathy, Baylor University, COVID-19, Second Sight, Orion, NIH, Light, Population, Glaucoma, Visual cortex, Perception, SEC, Disease, NASDAQ, Electrode, Severe cognitive impairment, Form, Risk management, the Orion Visual Cortical Prosthesis System, Second Sight Medical Products, Inc., THE ORION VISUAL CORTICAL PROSTHESIS SYSTEM, SECOND SIGHT MEDICAL PRODUCTS, INC.

The entirety of the $155,964 grant supplement will be provided to UCLA as a subcontractor to conduct the study.

Key Points: 
  • The entirety of the $155,964 grant supplement will be provided to UCLA as a subcontractor to conduct the study.
  • The grant supplement is related to the $6.4 million NIH grant for the Early Feasibility Clinical Trial of a Visual Cortical Prosthesis, grant UH3NS103442.
  • Second Sight reported promising two-year data from the Orion trial on May 12, 2021.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.